Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02776982 · ClinicalTrials.gov registry record · NA
Influence of Central Obesity on the Esophageal Epithelial Barrier
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT02776982: Completed NA study, sponsored by Mayo Clinic.
NCT02776982 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02776982, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study is being done to help understand why some people with an increased amount of central obesity, without gastroesophageal reflux, develop changes to the lining of their esophagus that can potentially lead to esophageal adenocarcinoma (cancer).
Interventions
- PROCEDURE Confocal endomicroscopy
- PROCEDURE Mucosal impedance
- PROCEDURE Research biopsies
- PROCEDURE Bravo ambulatory pH monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-11 |
| Est. Completion | 2019-05-16 |
| Phase | NA |
What the finished NCT02776982 record still lists
NCT02776982 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which Confocal endomicroscopy is the first listed.
NCT02776982 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02776982 about?
NCT02776982 is a clinical study titled "Influence of Central Obesity on the Esophageal Epithelial Barrier". This study is being done to help understand why some people with an increased amount of central obesity, without gastroesophageal reflux, develop changes to the lining of their esophagus that can potentially lead to esophageal adenocarcinoma (cancer).
What is the current status of trial NCT02776982?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2016-11. Estimated completion is 2019-05-16.
What interventions are being tested in trial NCT02776982?
The interventions under investigation include: Confocal endomicroscopy (PROCEDURE), Mucosal impedance (PROCEDURE), Research biopsies (PROCEDURE), Bravo ambulatory pH monitor (PROCEDURE).
Who is sponsoring clinical trial NCT02776982?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02776982's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia